Ganslandt, C., Maher, T., Molyneaux, P., Lindmark, B., Raud, J., Tornling, G., . . . Rosendahl, E. (2024). Buloxibutid, A Novel Angiotensin II Type 2 Receptor Agonist, Stabilized and Improved Lung Function in Individuals With Idiopathic Pulmonary Fibrosis in the 36-week Phase 2 AIR Trial. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 209, a1055.
Chicago-referens (17:e uppl.)Ganslandt, C., TM Maher, PL Molyneaux, BE Lindmark, J. Raud, G. Tornling, T. Bengtsson, och E. Rosendahl. "Buloxibutid, A Novel Angiotensin II Type 2 Receptor Agonist, Stabilized and Improved Lung Function in Individuals With Idiopathic Pulmonary Fibrosis in the 36-week Phase 2 AIR Trial." AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 209 (2024): a1055.
MLA-referens (9:e uppl.)Ganslandt, C., et al. "Buloxibutid, A Novel Angiotensin II Type 2 Receptor Agonist, Stabilized and Improved Lung Function in Individuals With Idiopathic Pulmonary Fibrosis in the 36-week Phase 2 AIR Trial." AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 209, 2024, p. a1055.
